Merck to Acquire Bio-Techne for $11.3 bn – What our Life Science Market Data Tells Us
5
Min Read
In this blog:
- Discover more about the Merck-Bio-Techne acquisition
- Uncover what CiteAb's citation-based market data reveals about each company's current standing
- Download data on the companies’ rankings across key reagent markets
CiteAb collects data on product use from the scientific literature. This citation data is a reliable proxy for market share, providing a record of past sales, and a leading indicator for future purchasing decisions, as researchers look to citations to inform purchasing decisions.
Announced just last week, Merck KGaA, Darmstadt, Germany, are set to acquire Bio-Techne (NASDAQ:TECH). Valued at approximately $11.3 billion, this move would bring together two major two life science research giants.
Our citation data analysis shows that both companies ranked in the top 10 by share in research antibody, protein and bioactive small molecule markets – making the potential impact of this life science M&A significant.
Below, we provide an overview of this acquisition and add our own data-driven perspective on what it could mean for the life science tools market.
Plus, download data on Merck and Bio-Techne’s market rankings for your own analysis at the bottom of this blog.
Companies’ Perspective
As the third largest biopharma M&A deal announced in 2026, the acquisition pairs Bio-Techne’s strengths in cytokines, growth factors, antibodies, and immunoassay kits – plus the instrumentation capabilities it gained through its ProteinSimple and Lunaphore acquisitions – with Merck’s scale, manufacturing expertise, and customer reach. [1]
Together, the companies are well placed to support fast-growing areas of research including multi-omics, cell and gene therapy, and spatial biology.
This deal builds on previous Merck acquisitions in the life science space, such as Mirus Bio in 2024 and SpringWorks Therapeutics in 2025. Previous CEO Garijo commented on their ‘appetite for M&A’, and new CEO Beckmann said that this was an ‘important milestone towards delivering on our mid- to long-term strategic agenda.’
Upon announcement of the deal, Bio-Techne shares rose by 19%. [2,3]
To sum up, the expected benefits from this acquisition include:
- Organisational opportunities
- Strengthening global reach
- Adding ‘differentiated technologies’ for life scientists
Press Release:
https://investors.bio-techne.com/press-releases/detail/535/merck-kgaa-darmstadt-germany-agrees-to-acquire
CiteAb Insight: Life Science Market Data Analysis into Merck and Bio-Techne
Overview
The CiteAb database covers 16M+ reagents from over 700 suppliers and their use in 40M publications, giving unique, quantitative insight into performance.
Our analysis shows that this deal will has the potential to significantly impact life science reagent markets, combining complementary strengths and cementing dominance in some areas.
In the antibody market, the acquisition may help improve the companies’ competitiveness, as well as in bioactives. In the protein and instrument space, the deal may bring interesting synergies.
Research Antibody Analysis
The research antibody market is a significant and growing segment with over 9 million products available, with estimated value of over $4 billion. [4,5] We commented over ten years ago on Merck’s acquisition of Sigma-Aldrich, a move that cemented them as a global leader in the antibody space and the third-largest player by citation share at the time.
Our latest analysis into the global antibody market reveals that MilliporeSigma, the US life science business of Merck, remains a strong presence in antibodies with a share of over 6%. (Though our data shows that share has been gradually declining.)
Bio-Techne, taking in both their R&D Systems and Novus Biologicals brands, also rank as a top 10 antibody supplier.
Combining both companies’ 2025 market share to give a rough indication of the potential impact of this deal indicates they would jump up to 5th position, improving either company’s standalone ranking.
In such a large and competitive market, this offers an opportunity for the combined company to compete more efficiently with leaders such as Abcam and Cell Signaling Technology.
Protein, ELISA Kit, and Bioactive Small Molecule Analysis
Given Bio-Techne’s positioning as a leader in recombinant proteins, we looked at their citation share in this area. Over the past five years, they ranked overall as the 5th most cited supplier. MilliporeSigma, the US life science business of Merck is dominant in the protein space overall, with nearly a third of the market.
It is worth noting that Bio-Techne have a particular strength in the growth factor market, ranking as the 2nd most cited supplier, ahead of MilliporeSigma.
The synergy in offerings could make for strong improvements for the companies.
When we looked at the bioactive small molecule space, we saw the same pattern. We discovered that MilliporeSigma dominated here, with over a third of the market’s citation share in 2025. Tocris Bioscience, a Bio-Techne brand also had a prominent share, as the 6th most cited supplier in the space.
Combining the companies gives them joint strength, cementing them at number one.
R&D Systems, a Bio-Techne brand, have also been leaders in the ELISA Kit space. This acquisition will bring the number one supplier into Merck.
Instrument Analysis
With the acquisitions of Lunaphore, ACDBio and ProteinSimple, Bio-Techne are strongly placed in the instrument market. This could support growth in Merck’s positioning.
We noticed an overall positive trajectory for Lunaphore, who focus on multiplex solutions for spatial biology applications, and ACDBio, who supply RNAscope products. We also found that ProteinSimple, who specialise in protein detection and analysis instruments, sat within the top 40 for instrument suppliers overall.
Andrew Chalmers, CEO of CiteAb commented:
‘Merck and Bio-Techne support a significant number of researchers with their reagents. Combining two strong catalogues cements the companies’ rankings in competitive markets and offers some interesting synergies.’ He added: ‘We will be monitoring the citation share of the combined company closely to see the effects of this acquisition plays out, and the impact for life scientists. ’
Wrap-up and Data Download
This acquisition demonstrates how companies are continuing to grow their portfolios to serve more scientists in the bioscience space. It also fits with a pattern we have seen recently of consolidation of large companies, such as the acquisition of Abcam by Danager, BioLegend by PerkinElmer, and BD Biosciences by Waters.
We’ll continue monitoring our data and sharing updates as market shifts like this unfold.
Finally, we are giving away a free data download on the ranks of both companies in the research antibody, protein, instrument and bioactive small molecule markets.
For more insights into reagent market trends, get in touch with the CiteAb team to learn how our data solutions can support strategy and market analysis.
Sign up for data
Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.
References
- https://www.genengnews.com/topics/bioprocessing/merck-kgaa-to-acquire-bio-techne-for-11-3b-expanding-life-science-tools-presence/
- https://www.reuters.com/business/healthcare-pharmaceuticals/germanys-merck-buy-bio-techne-73-per-share-2026-06-25/
- https://www.fiercepharma.com/pharma/merck-kgaa-throws-down-113b-bio-techne-biggest-deal-2015-sigma-aldrich-buy
- https://www.futuremarketinsights.com/reports/research-antibodies-market
- https://www.mordorintelligence.com/industry-reports/research-antibodies-market
